Literature DB >> 15195055

c-met overexpression in supraglottic laryngeal squamous cell carcinoma and its relation to lymph node metastases.

O Taskin Yücel1, Arzu Sungur, Sefa Kaya.   

Abstract

BACKGROUND: The c-met oncogene encodes the receptor for the hepatocyte growth factor/scatter factor (HGF/SF), which is known to have the effects of stimulation of cell motility, dissociation of epithelial sheets, invasion of cellular matrix, and induction of angiogenesis. Many studies in solid tumors have indicated a role for c-met and HGF/SF in the progression of the disease.
METHODS: The expression of c-met in tissue specimens was studied by immunohistochemical examination in 60 patients with supraglottic laryngeal squamous cell carcinoma. Patients were chosen such that there were 30 with lymph node metastases in the neck and 30 without metastases. TNM staging, differentiation, lymphovascular and perineural invasion, and growth pattern for tumors were also recorded, and their relation to lymph node metastases was analyzed.
RESULTS: Overexpression of c-met was observed in 90% of the cases at the primary site and in 83% of the cases with lymph node metastases in the neck. Lymphovascular invasion (P = 0.005) and the N stage (P = 0.001) were found to be related to lymph node metastases, but other variables-c-met overexpression, the T stage, perineural invasion, and growth pattern-were found to have no relation to lymph node metastases in multivariate analysis of the data with linear regression.
CONCLUSIONS: c-met overexpression is observed in both the primary site and the neck in supraglottic laryngeal squamous cell carcinoma. We believe that it may have a role in the progression of malignancy, but we were unable to find a definite relation between c-met expression and lymph node metastases.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15195055     DOI: 10.1016/j.otohns.2003.09.031

Source DB:  PubMed          Journal:  Otolaryngol Head Neck Surg        ISSN: 0194-5998            Impact factor:   3.497


  6 in total

1.  The MET receptor tyrosine kinase is a potential novel therapeutic target for head and neck squamous cell carcinoma.

Authors:  Tanguy Y Seiwert; Ramasamy Jagadeeswaran; Leonardo Faoro; Varalakshmi Janamanchi; Vidya Nallasura; Mohamed El Dinali; Soheil Yala; Rajani Kanteti; Ezra E W Cohen; Mark W Lingen; Leslie Martin; Soundararajan Krishnaswamy; Andres Klein-Szanto; James G Christensen; Everett E Vokes; Ravi Salgia
Journal:  Cancer Res       Date:  2009-03-24       Impact factor: 12.701

2.  Prognostic role of c-met expression in breast cancer patients.

Authors:  Iwona Gisterek; Ewelina Lata; Agnieszka Halon; Rafal Matkowski; Jolanta Szelachowska; Przemyslaw Biecek; Jan Kornafel
Journal:  Rep Pract Oncol Radiother       Date:  2011-06-08

3.  NK4 Regulates Laryngeal Squamous Cell Carcinoma Cell Properties and Inhibits Tumorigenicity by Modulating the DKK1/Wnt/β-Catenin Axis.

Authors:  Shoukai Zhang; Hulai Wei; Xiaoqin Ha; Yueyu Zhang; Yufen Guo
Journal:  Front Oncol       Date:  2021-12-14       Impact factor: 6.244

Review 4.  Cancer therapy using tumor-associated antigens to reduce side effects.

Authors:  David Siu
Journal:  Clin Exp Med       Date:  2009-05-01       Impact factor: 5.057

5.  Clinicopathological impacts of high c-Met expression in head and neck squamous cell carcinoma: a meta-analysis and review.

Authors:  Jung Han Kim; Bum Jun Kim; Hyeong Su Kim
Journal:  Oncotarget       Date:  2017-09-28

6.  Met degradation by SAIT301, a Met monoclonal antibody, reduces the invasion and migration of nasopharyngeal cancer cells via inhibition of EGR-1 expression.

Authors:  B-S Lee; S Kang; K-A Kim; Y-J Song; K H Cheong; H-Y Cha; C-H Kim
Journal:  Cell Death Dis       Date:  2014-04-10       Impact factor: 8.469

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.